Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1645 1657 1674
This examiner grants 72% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18054660 | SINGLE-STRANDED OLIGONUCLEOTIDE | Final Rejection | NISSAN CHEMICAL CORPORATION |
| 19460949 | COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION | Non-Final OA | NOVO NORDISK A/S |
| 18021469 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17636481 | METHOD OF MODULATING ADIPOSITY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18272933 | ENGINEERED NUCLEIC ACIDS TARGETING LONG NONCODING RNA INVOLVED IN PATHOGENIC INFECTION | Final Rejection | President and Fellows of Harvard College |
| 18577903 | Yeast Single Nucleotide Polymorphisms for Industrially Relevant Phenotypes | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 16954171 | CRISPR-MEDIATED GENOME EDITING WITH VECTORS | Final Rejection | Regents of the University of Minnesota |
| 17814211 | ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS) | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17920342 | COMPOSITIONS AND METHODS FOR INTRANASAL TREATMENT WITH DOUBLE STRANDED RNA | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18069387 | ENGINEERED NUCLEASES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 17910497 | NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18490131 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | Non-Final OA | The Board of Regents of The University of Texas System |
| 18471280 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | Non-Final OA | The Board of Regents of The University of Texas System |
| 18019720 | Human XIST Antisense Oligonucleotides for X Reactivation Therapy | Non-Final OA | The General Hospital Corporation |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17930042 | AMPHIPHILIC OLIGODEOXYNUCLEOTIDE CONJUGATES AS ADJUVANT ENHANCERS | Final Rejection | Wayne State University |
| 18176396 | STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE | Non-Final OA | University of Miami |
| 17908135 | COMPOUNDS AND METHODS FOR MODULATING KCNQ2 | Non-Final OA | Ionis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy